Business
Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines.
About this update from Mymetics Corp.
[{"type":"text","content":"\n\n\n\nMymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines\nPR Newswire\nEPALINGES, Switzerland, Sept. 13, 2017\n\n\n\nEPALINGES, Switzerland, Sept. 13, 2017 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that they will present new preclinical data. The new data demonstrates that nasal powder, oral capsules and sublingual tablets developed by MACIVIVA partners, containing Mymetics HIV-1 virosome based vaccine candidate, could induce specific antibody immune response in rodent and mini-pig animal models.\n\nThe results are generated under the MACIVIVA project, an EU Horizon 2020 project, which stands for \"Manufacturing process for Cold-chain Independent Virosome-based Vaccines.\" The project started in May 2015, with a duration of total 3.5 years and brings together leading contract manufacturers and the relevant expertise for spray drying, freeze drying and analytical techniques from the pharmaceutical industry to develop a scalable manufacturing process to achieve thermostable and cold-chain independent virosome based vaccines.\n\nThe new preclinical data will be presented at three upcoming events. \n\n\n12 – 14 September, 2017: Modern Vaccines Adjuvants & Delivery Systems, Porto, Portugal.\n16 – 18 September, 2017: ILS Liposome Advances & Liposome Research, Athens, Greece.\n10 – 12 October, 2017: World Vaccine Congress Europe, Barcelona, Spain.\nThe preliminary results are showing that spray drying and lyophilization may conserve the virosome structure and antigens during the manufacturing process. Preclinical studies showed that Mymetics HIV-1 vaccine candidate, after being downstream processed into different powder solid dosage forms, could trigger specific antibodies, which were varia...